Pfizer's ELREXFIO Receives U.S. FDA Accelerated Approval For Relapsed Or Refractory Multiple Myeloma
Portfolio Pulse from Happy Mohamed
Pfizer Inc. (NYSE:PFE) has received accelerated approval from the U.S. FDA for ELREXFIO (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma. The approval is based on the results of the Phase 2 MagnetisMM-3 trial. Pfizer is also advancing the MagnetisMM clinical program to expand ELREXFIO into earlier lines of treatment. The approval of ELREXFIO is based on data from response rates and duration of response.
August 14, 2023 | 6:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pfizer's new drug ELREXFIO has received accelerated approval from the FDA. This could potentially boost Pfizer's revenues and strengthen its position in the healthcare sector.
The FDA's accelerated approval of Pfizer's ELREXFIO indicates a positive outlook for the company. This approval could lead to increased sales and revenues for Pfizer, as the drug is now available for use in the treatment of relapsed or refractory multiple myeloma. Furthermore, this could also strengthen Pfizer's position in the healthcare sector, as it continues to develop and introduce new treatments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100